[Drug-induced exanthema caused by pegylated interferon-alpha 2b].
D000284:Administration, Oral; D000998:Antiviral Agents / Q000009:adverse effects*; D003875:Drug Eruptions / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology*; D005076:Exanthema / Q000139:chemically induced* / Q000175:diagnosis / Q000188:drug therapy; D005260:Female; D005938:Glucocorticoids / Q000008:administration & dosage / Q000627:therapeutic use; D006633:Histamine Antagonists / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects*; D008875:Middle Aged; D009824:Ointments; D011092:Polyethylene Glycols; D011994:Recombinant Proteins; D012882:Skin Tests
D000998:Antiviral Agents; D005938:Glucocorticoids; D006633:Histamine Antagonists; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D009824:Ointments; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; C417083:peginterferon alfa-2b; C100416:peginterferon alfa-2a